SEC Comment Letter 0000000000-23-012533 to FATE THERAPEUTICS INC (FATE) (CIK 0001434316) (FATE)
FATE THERAPEUTICS INC (FATE) (CIK 0001434316)
Date: Nov. 15, 2023 · CIK: 0001434316 · Accession: 0000000000-23-012533
AI Filing Summary & Sentiment
File numbers found in text: 333-275402
Letter
United States securities and exchange commission logo November 15, 2023 J. Scott Wolchko President and Chief Executive Officer Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego, CA 92131 Re:Fate Therapeutics, Inc. Registration Statement on Form S-3 Filed November 8, 2023 File No. 333-275402 Dear J. Scott Wolchko: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Natalie T. Martirossian, Esq.
Show Raw Text
United States securities and exchange commission logo
November 15, 2023
J. Scott Wolchko
President and Chief Executive Officer
Fate Therapeutics, Inc.
12278 Scripps Summit Drive
San Diego, CA 92131
Re:Fate Therapeutics, Inc.
Registration Statement on Form S-3
Filed November 8, 2023
File No. 333-275402
Dear J. Scott Wolchko:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Natalie T. Martirossian, Esq.